In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer TreatmentsPedro Nazareth Aguiar, Gilberto Lopes, Jacob J. Adashek et al.|Value in Health Regional Issues|2019Cited by 22
Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancerPedro Nazareth Aguiar, Gilberto Lopes, Pui San Tan et al.|Einstein (São Paulo)|2019Cited by 19
The efficacy of placebo for the treatment of cancer-related fatigue: a systematic review and meta-analysisPedro Nazareth Aguiar, Auro del Giglio, Carmélia Maria Noia Barreto et al.|Supportive Care in Cancer|2019Cited by 18
A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitorsMariane Teodoro Fernandes, Pedro Nazareth Aguiar, Jacob J. Adashek et al.|Drugs in Context|2018Cited by 11
Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer.Pedro Nazareth Aguiar, Gilberto Lopes, Pui San Tan et al.|Journal of Clinical Oncology|2018Cited by 7